Industry-academia collaboration key to strengthening pharma R&D
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
In FY 2020-2021 (upto 12th January 2021) Jan Aushadhi Kendras have completed sales of Rs. 484 crores at 7,064 Pradhan Mantri Bhartiya Jan Aushadhi Kendras
Subscribe To Our Newsletter & Stay Updated